Harvard Bioscience reports Q1 adjusted EPS (1c) vs. 2c last year

Reports Q1 revenue $21.8M vs. $24.5M last year. Jim Green, Chairman and CEO, said, “First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China. We are excited by the emerging adoption of our breakthrough MeshMEA organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo telemetry systems. In addition, we remain focused on managing costs and expect that recently completed cost reduction actions will result in operating cost reductions of approximately $1 million per quarter beginning in the second quarter.”